A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
2015; Elsevier BV; Volume: 125; Issue: 26 Linguagem: Inglês
10.1182/blood-2014-12-614636
ISSN1528-0020
AutoresAchim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, M. Ravic, Stefan Knackmuss, Jens‐Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert,
Tópico(s)CAR-T cell therapy research
ResumoKey Points The bispecific, tetravalent antibody AFM13 represents a new approach engaging natural killer cells via CD16A to fight CD30+ malignancies. AFM13 is well tolerated and active in Hodgkin lymphoma patients who received all standard therapies, including brentuximab vedotin.
Referência(s)